Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence. [Wikipedia]
solifenacin succinate dosage
A fixed-dose combination (FDC) tablet of Tamsulosin oral controlled absorption system (OCAS) 0.4 mg and solifenacin succinate 6 mg (Vesomni™, Astellas Pharma Europe BV, Leiden, the Netherlands) has been recently authorized for use in men with moderate-to-severe storage symptoms and voiding symptoms associated with BPH, not adequately responding to treatment with monotherapy.
Patients in group I (n = 84) received no treatment (control group) (C group), patients in group II (n = 85) received a daily oral dose of Tamsulosin 0.4 mg (T group), patients in group III (n = 84) received solifenacin succinate 10 mg (S group), and patients in group IV (n = 85) received a combination of the two medications once daily (T/S group).
We added an anticholinergic, solifenacin 5 mg (Vesicare, Astellas Pharm Manufacturing Inc., Tokyo, Japan), to low-dose triple therapy and investigated the findings after administration for 8 weeks.
A randomized, double-blind, active and placebo-controlled, multicenter dose-ranging study is currently underway to evaluate the efficacy, safety, and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies for treating overactive bladder.
There are no spectrophotometric methods reported for the estimation of solifenacin succinate in the pharmaceutical dosage form.
Taking into account the above-mentioned characteristics, two accurate, simple, precise, economical, and rapid, visible spectrophotometric assay methods were developed, for the quantitative estimation of solifenacin succinate in tablet dosage forms.